Want to see LXRX full AI Analyst Report?
LXRX Stock Chart & Stats
$1.87
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.87
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$1.00 - $2.68
Previous CloseN/A
Volume2.02M
Average Volume (3M)3.78M
Market Cap
$986.12M
Enterprise Value$925.78M
Total Cash (Recent Filing)$170.66M
Total Debt (Recent Filing)$57.71M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Jul 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding444,196,380
10 Day Avg. Volume2,962,417
30 Day Avg. Volume3,781,620
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue13.29
Enterprise Value/Gross Profit13.42
Enterprise Value/Ebitda-53.08
Forecast
1Y Price Target
$5.03Price Target Upside169.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$38.17M
Bulls Say, Bears Say
Bulls Say
Revenue Momentum & Strong Gross MarginsLexicon demonstrated a material step-up in revenue driven by milestone recognition and reports exceptionally high gross margins (~99%). Durable implication: when revenue is realized, it is highly accretive at the gross level, supporting scalable contribution to margins as recurring sales or milestones recur.
Strengthened Liquidity And Capital FlexibilityCash reserves nearly $200M and a secured $100M term facility (initial tranche funded) materially extend runway versus year-end. This reduces near-term refinancing risk and funds late-stage trials and regulatory activities, improving the company’s ability to execute multi-quarter development plans.
Late-stage Pipeline Progress And Partner ValidationAdvancing SONATA to completion, a targeted NDA resubmission for Zynquista, and partner-triggered Phase I milestones signal de-risking of late-stage assets and external validation from collaborators. These durable program milestones increase the probability of future regulatory or milestone-driven value realization.
Bears Say
Milestone-driven, Lumpy Revenue ProfileA substantial portion of near-term revenue is one-time, partner-triggered milestones rather than organic product sales. Structurally, this creates volatility in cash flows and planning uncertainty: sustainable operating performance depends on converting milestones into recurring commercial revenue or additional partner deals.
Persistent Negative Operating Cash FlowDespite improvement versus prior years, TTM operating and free cash flow remain substantially negative, indicating the business still consumes cash to fund R&D and operations. Over months, continued burn risks eroding liquidity absent recurring revenue, further financing, or meaningful margin expansion.
Conditional Tranches And Covenanted Debt StructureThe term loan’s additional tranches are contingent on clinical and regulatory milestones and include tightening covenants after draws. Structurally, access to the full facility is uncertain and covenants/first-lien security could constrain flexibility if clinical timelines slip.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.00 and its highest was $2.68 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $986.12M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 16 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on May 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.034.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,196,380 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.03 (169.16% Upside)
$5.03 (169.16% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 41.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.46%
12-Months-Change
Fundamentals
Return on Equity
-18.64%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX Stock 12 Month Forecast
Average Price Target
$5.03
▲(169.16% Upside)
Technical Analysis
Ownership Overview
61.20% Insiders
7.54% Mutual Funds
0.73% Other Institutional Investors
27.94% Public Companies and
Individual Investors